Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype.

Pharmacological research - 1 Feb 2007

García-Quetglas Emilio, Azanza José Ramón, Sádaba Belén, Muñoz María José, Gil Isabel, Campanero Miguel Angel

Abstract excerpt

OBJECTIVE: Our objective was to evaluate the effect of CYP2D6 phenotype in the enantioselective metabolism of tramadol in Spanish healthy human volunteers. METHODS: A single oral 100mg dose of racemic tramadol was administered to five subjects who were poor metabolizers (PMs) and 19 subjects who were extensive metabolizers (EMs), whose phenotypes were determined by the use of the racemic tramadol metabolic rate....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Analgesics, Opioid
Share to Area Under Curve

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Epinephrine

Share to Phenotype

Share to Polymorphism, Genetic

Share to Stereoisomerism

Source

Identifiers

PMID: 17175164
DOI: 10.1016/j.phrs.2006.11.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype.PMID 17175164Read ↗

Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of CYP2D6, CYP2B6, and CYP3A4 genotype.Semantic proximity Read ↗

Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes.Semantic proximity Read ↗

Assessment of tramadol pharmacokinetics in correlation with CYP2D6 and clinical symptoms.Semantic proximity Read ↗

Miotic action of tramadol is determined by CYP2D6 genotype.Semantic proximity Read ↗

Influence of CYP2D6 phenotype on the pharmacokinetics and pharmacodynamics of tramadol in patients treated for post-operative pain management.Semantic proximity Read ↗

Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study.Semantic proximity Read ↗

Impact of CYP genotype and inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients.Semantic proximity Read ↗

Physiologically based pharmacokinetic modeling of tramadol to inform dose adjustment and drug-drug interactions according to CYP2D6 phenotypes.Semantic proximity Read ↗

Role of Pharmacogenetics on Tramadol Pharmacokinetics: A Population Pharmacokinetic Model.Semantic proximity Read ↗

CYP2D6 polymorphism in relation to tramadol metabolism: a study of faroese patients.Semantic proximity Read ↗

Tramadol-Related Deaths: Genetic Analysis in Relation to Metabolic Ratios.Semantic proximity Read ↗

Effects of type 1 and type 2 diabetes on the pharmacokinetics of tramadol enantiomers in patients with neuropathic pain phenotyped as cytochrome P450 2D6 extensive metabolizers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.